Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ideaya Biosciences Inc (NQ: IDYA )

24.56 -0.31 (-1.25%)
Streaming Delayed Price Updated: 2:55 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ideaya Biosciences Inc

< Previous 1 2 3 Next >
IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial
 
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises
Pre-open movers 
Via Benzinga
Why IDEAYA Biosciences Shares Plunging Today
 
Via Benzinga
Recap: IDEAYA Biosciences Q1 Earnings
IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Oracle, JPMorgan And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Looking Into IDEAYA Biosciences's Return On Capital Employed
Benzinga Pro data, IDEAYA Biosciences (NASDAQ:IDYA) reported Q2 sales of $5.85 million. Earnings fell to a loss of $22.06 million, resulting in a 57.4% decrease from last quarter. 
Via Benzinga
IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia
IDEAYA Biosciences (NASDAQ: IDYA) has initiated Investigator Sponsored Trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM)... 
Via Benzinga
IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
AppLovin, Unity Software And Some Other Big Losers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining around 150 points. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
Via Benzinga
Gold Drops Over 1%; Viridian Therapeutics Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones around 170 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Stocks Trim Morning Losses Ahead Of Retail Earnings
Investors are eyeing an influx of earnings from the retail sector later in the week. 
Via Talk Markets
Dow Surges Over 100 Points; Crude Oil Falls Sharply
U.S. stocks traded turned higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. 
Via Benzinga
U.S. Stocks Edge Lower; NY Empire State Manufacturing Index Drops In August
U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday. 
Via Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New... 
Via Benzinga
Recap: IDEAYA Biosciences Q2 Earnings
  IDEAYA Biosciences (NASDAQ:IDYA) reported its Q2 earnings results on Monday, August 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings IDEAYA Biosciences missed... 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
IDEAYA's Cancer Candidate Shows Early Tumor Modulation
 
Via Benzinga
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
 
Via Benzinga
FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma
The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced  
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: IDEAYA Biosciences Q4 Earnings
IDEAYA Biosciences (NASDAQ:IDYA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
IDEAYA Biosciences's Earnings: A Preview
IDEAYA Biosciences (NASDAQ:IDYA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.